IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Why now
Thesis: Routine equity grant disclosure, low market relevance
Catalyst to watch: None; standard listing-rule filing
Main risk: Small shareholder dilution over time
Why it matters
Inducement grants are routine Nasdaq listing compliance and dilute only marginally.
Details
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of...
Sources
- prnewswire · 2026-09-25 10:00 UTC